5269-60-3

Basic information

• Product Name: trimethylsilyl leucinate
• Synonyms: leucine, trimethylsilyl ester
• CAS NO: 5269-60-3
• Molecular Formula: C₉H₂₁NO₂Si
• Molecular Weight: 203.354
• Mol File: 5269-60-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 212.8°C at 760 mmHg
• Flash Point: 82.5°C
• Density: 0.921g/cm³
• Vapor Pressure: 0.17mmHg at 25°C
• Refractive Index: 1.435
• CAS DataBase Reference: trimethylsilyl leucinate(CAS DataBase Reference)
• NIST Chemistry Reference: trimethylsilyl leucinate(5269-60-3)
• EPA Substance Registry System: trimethylsilyl leucinate(5269-60-3)

Safety Data

• Hazardous Substances Data: 5269-60-3(Hazardous Substances Data)

Usage

General Description

Trimethylsilyl leucinate is a chemical compound that is a derivative of leucine, an essential amino acid. trimethylsilyl leucinate is commonly used in organic synthesis as a protecting group for the carboxylic acid group of amino acids. By adding a trimethylsilyl group to the carboxylic acid group, the reactivity of the amino acid is decreased, allowing for selective reactions to occur elsewhere in the molecule. Trimethylsilyl leucinate plays a crucial role in peptide synthesis, allowing chemists to selectively protect and deprotect the carboxylic acid group, enabling the creation of complex peptides and proteins. Additionally, the trimethylsilyl group is easily removed under mild conditions, making it a versatile tool for synthetic chemists.

Upstream product

• 10416-59-8 N,O-bis-(trimethylsilyl)-acetamide 
• 61-90-5 L-leucine 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 2002-44-0 melanostatin 
• 362626-20-8 (PhAcOZ-Leu-Cys-OAll)2 
• 283176-54-5 PhAcOZ-Leu-OH 
• 32225-38-0 (L)-Trt-Leu-OH 

Relevant articles and documents

De-novo designed library of benzoylureas as inhibitors of BCL-X L: Synthesis, structural and biochemical characterization

The prosurvival BCL-2 proteins are attractive yet challenging targets for medicinal chemists. Their involvement in the initiation and progression of many, if not all, tumors makes them prime targets for developing new anticancer therapies. We present our approach based on de novo structure-based drug design. Using known structural information from complexes engaging opposing members of the BCL-2 family of proteins, we designed peptidomimetic compounds using a benzoylurea scaffold to reproduce key interactions between these proteins. A library stemming from the initial de novo designed scaffold led to the discovery of ligands with low micromolar potency (KD = 4 μM) and selectivity for BCL-XL. These compounds bind in the canonical BH3 binding groove in a binding mode distinct from previously known BCL-2 inhibitors. The results of our study provide insight into the design of a new class of antagonists targeting a challenging class of protein-protein interactions.

ALPHA-HELICAL MIMETICS

Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralising pro-survival Bcl-2 proteins. Use of the benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also disclosed.

SYNTHESIS OF THE AMIDE OF THE C-TERMINAL TETRAPEPTIDE OF THE SEQUENCE OF OXYTOCIN

The synthesis has been effected of the amide of the tetrapeptide forming the sequence 6-9 of oxytocin with the use of benzyl protection of the thiol function of cysteine by two main schemes 1+3 and 2+2.The advantageousness of performing the synthesis by the 2+2 scheme has been shown.The overall yield of tetrapeptide using the method of condensation with the formation of mixed anhydrides amounted to 51percent by the scheme proposed.